This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
COLEMAN, ROBERT
| Item Type | Name |
|
Concept
|
Benzimidazoles
|
|
Academic Article
|
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
|
|
Academic Article
|
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
|
|
Academic Article
|
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
|
|
Academic Article
|
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
|
|
Academic Article
|
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
|
|
Academic Article
|
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
|
|
Academic Article
|
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
|
|
Academic Article
|
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
|
|
Academic Article
|
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
|